|
|
|
|
|
|
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ TerminatedNot Applicable [Translation] HDM3706 Fasting and Postprandial Human Bioequivalence Preliminary Study
研究健康试验参与者在空腹或餐后状态下,单次口服由杭州中美华东制药江东有限公司提供的布地奈德肠溶胶囊(受试制剂T1/T2,规格:4mg)与相同状态下单次口服由Calliditas Therapeutics AB持证的布地奈德肠溶胶囊(参比制剂R,商品名:耐赋康®,规格:4mg)的药动学特征,比较制剂间药动学参数AUC和Cmax的差异,初步评估受试制剂和参比制剂生物等效趋势。
[Translation] The study compared the pharmacokinetic characteristics of budesonide enteric-coated capsules (test formulation T1/T2, strength: 4mg) supplied by Hangzhou Sino-American East China Pharmaceutical Jiangdong Co., Ltd., in both fasting and postprandial states, with those of budesonide enteric-coated capsules (reference formulation R, trade name: Nefukang®, strength: 4mg) certified by Calliditas Therapeutics AB, in the same state. The differences in pharmacokinetic parameters AUC and Cmax between the two formulations were compared to preliminarily assess the bioequivalence trend between the test and reference formulations.
/ TerminatedNot Applicable [Translation] HDM3706 Fasting and Postprandial Human Bioequivalence Preliminary Study
研究健康研究参与者在空腹或餐后状态下,单次口服由杭州中美华东制药江东有限公司提供的HDM3706(受试制剂T1/T2,规格:4mg)与相同状态下单次口服由Everest Medicines (Singapore) Pte.Ltd.持证的参比制剂(参比制剂R,商品名:NEFECON®,规格:4mg)的药动学特征,比较制剂间药动学参数AUC和Cmax的差异,初步评估受试制剂和参比制剂生物等效趋势。
[Translation] The pharmacokinetic characteristics of participants in the health study were compared between a single oral dose of HDM3706 (test formulation T1/T2, strength: 4 mg) provided by Hangzhou Sino-American East China Pharmaceutical Jiangdong Co., Ltd., under fasting or postprandial conditions, and a single oral dose of a reference formulation (reference formulation R, trade name: NEFECON®, strength: 4 mg) certified by Everest Medicines (Singapore) Pte. Ltd., under the same conditions. The differences in pharmacokinetic parameters AUC and Cmax between the two formulations were compared to preliminarily assess the bioequivalence trend between the test and reference formulations.
/ TerminatedNot Applicable [Translation] Preliminary bioequivalence study of HDM3706 in fasting and fed subjects
研究健康研究参与者在空腹或餐后状态下,单次口服由杭州中美华东制药江东有限公司提供的HDM3706(受试制剂T1/T2,规格:4mg)与相同状态下单次口服参比制剂(参比制剂R,规格:4mg)的药动学特征,比较制剂间药动学参数AUC和Cmax的差异,初步评估受试制剂和参比制剂吸收动力学的一致性。
[Translation] Methods: The pharmacokinetic characteristics of HDM3706 (test preparation T1/T2, strength: 4 mg) provided by Hangzhou Sino-US Huadong Pharmaceutical Jiangdong Co., Ltd. were investigated after a single oral dose in healthy study participants under fasting or fed conditions, compared with a single oral dose of the reference preparation (reference preparation R, strength: 4 mg) under the same conditions. The differences in the pharmacokinetic parameters AUC and Cmax between the preparations were compared, and the consistency of the absorption kinetics of the test preparation and the reference preparation was preliminarily evaluated.
100 Clinical Results associated with Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co
0 Patents (Medical) associated with Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co
100 Deals associated with Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co
100 Translational Medicine associated with Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co